Recludix Pharma Announces Leadership Expansion, Promotes Dr. Brian Hodous To Chief Scientific Officer

Recludix Pharma, a company focused on discovering inhibitors for challenging targets in inflammatory diseases, has announced updates to its leadership team. Brian Hodous, Ph.D., has been promoted to Chief Scientific Officer. Vivek (Vic) Kadambi, Ph.D., has been appointed as Senior Vice President of Non-Clinical Sciences and CMC. Kristin Polsenski, M.B.A., has expanded her responsibilities to include Chief of Staff to the CEO, in addition to her current role as Vice President of Portfolio, Program, and Alliance Management.

Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, stated, “We are fortunate to have assembled a world-class leadership team with deep expertise in translating scientific innovation through clinical development and into the hands of patients who need it most, and I’m excited to continue strengthening this exceptional team. Brian, a co-founder of the company, played a pivotal role in shaping our highly differentiated chemistry platform. His scientific vision has been instrumental in enabling the development of our potent SH2 inhibitors, successfully targeting a class once considered undruggable.”

He also added, “Brian’s experience building inhibitor platforms for novel targets is unparalleled, having previously co-led the advancement of Blueprint Medicines’ proprietary kinase inhibitor library, leading to his co-invention of products that have been commercialized or are under clinical development. We are also thrilled to welcome Vic to head our non-clinical sciences and CMC departments. With an impressive track record of advancing multiple first-in-class clinical and marketed therapies during his tenures at IDRx, Vertex, Blueprint, and Millennium/Takeda, Vic brings invaluable translational expertise to this key leadership role. Lastly, Kristin will strengthen our operational excellence as she brings extensive organizational expertise from her previous roles at Seagen and Zymeworks.”

Ajay Nirula, M.D., Ph.D., executive vice president and head of R&D, mentioned, “I am incredibly excited to work closely with these accomplished executives as we advance towards being a clinical-stage company. With such experienced drug developers leading scientific, operational, and development functions, we are exceptionally well positioned to advance our programs with focus and impact. I’m delighted to have Brian and Vic assume key responsibilities on my R&D leadership team.”

Dr. Hodous, chief scientific officer, explained, “It has been deeply gratifying to witness the evolution of what began as a formidable scientific challenge—targeting SH2 domains as a therapeutic strategy—into a successful platform with the potential to transform disease treatment. Our efforts have culminated in the development of multiple first-in-class oral inhibitors against well-validated disease targets, underscoring the remarkable capabilities of this approach. Looking ahead, I am energized by the opportunity to continue innovating with our exceptional scientific team. With over 120 SH2 domain-containing proteins in the human proteome and other currently ‘undruggable’ targets to explore, the opportunities to help patients remain vast and full of promise.”